The association of HER-2/neu over-expression in relation to p53 nuclear accumulation, hormonal recceptor status and common clinico-pathological prognostic parameters in a series of Egyptian women with invasive ductal carcinoma

European Journal of General Medicine

Volumn 4, Issue 2, 2007, Pages 73-79

  Rashed, Mona M ^a,c   Ragab, Noha M ^b   Galal, Manal K ^a  

^a General Organization for Teaching Hospitals and Institutes   (Egypt)

^b ALEXANDRIA UNIVERSITY   (Egypt)

^c NONE   (Egypt)

Author keywords

Breast cancer; Clinico pathological parameters; Her 2 neu; Hormone receptors; Immunohistochemistry; P53

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; PROTEIN P53; TUMOR MARKER;

ARTICLE; BREAST; BREAST CANCER; BREAST DUCT; CANCER GRADING; CANCER INVASION; CLINICAL ARTICLE; DISEASE ASSOCIATION; EGYPT; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MENOPAUSE; ONCOGENE NEU; PROGNOSIS; TUMOR NECROSIS; TUMOR VOLUME;

EID: 41449111435     PISSN: 13043889     EISSN: None     Source Type: Journal    
DOI: 10.29333/ejgm/82489     Document Type: Article

References (32)

1. Al-Moundhri M, Nirmala V, Al-Mawaly K, et al. Significance of p53, Bcl-2 and Her-2/neu protein expression in Omani Arab females with breast cancer. Pathol Oncol Res 2003;9:226-31
2. Yamashita H, Nishio M, Toyama T, et al. Coexistence of HER-2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 2004;6:24-30
3. Meenakshi A, Kumar RS, Ganesh V, et al. Immunohistochemical assay (IHC) to study C-erbB-2 status of breast cancer using monoclonal antibody CIBCgp185. Hum Antibodies 2003;12(4):123-7
4. Diaz NM. Laboratory testing for Her-2/neu in breast carcinoma: An evolving strategy to predict response to targeted therapy. Cancer Control 2001;8(5):415-8
5. Hudziak RM, Lewis GD, Shalaby MR, et al. Amplified expression of the HER-2/ErbB2 oncogene induces resistance to tumor necrosis factor alpha in NIH3T3 cells. Proc Natl Acad Sci USA 1988;85(14):5102-6
6. Zhou BP, Hu MC, Miller SA, et al. HER-2/neu blocks tumor necrosis factor induced apoptosis via the Akt/NF-kappa B pathway. J Biol Chem 2000;275(11):8027-31
7. Rosenblum MG, Horn SA & Cheung LH. A novel recombinant fusion toxin targeting HER-2/neu over expressing cells and containing human tumor necrosis factor. Int J Cancer 2000;88(2):267-73
8. Scarff RW, Torloni H. Histological typing of breast tumors. 1968 International histological classification of tumors. World Health Organization, Geneva,no2 vol2; pp 13-20
9. Hlupic L, Jakic-Razumovic J, Bozikov J, et al. Prognostic value of different factors in breast carcinoma. Tumori 2004;90(1):112-9
10. Sorli T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguishes tumor subclasses with clinical implication. PNAS 2001;98(19):10869-74
11. Winters ZE, Leek RD, Bradurn MJ, et al. Cytoplasmic p21 WAF1/CIP1 expression is correlated with HER-2/neu in breast cancer and is an independent predictor of prognosis. Breast Cancer Res 2003;5:242-9
12. Salmon DJ, Clark GM, Wong SG, et al. Human breast cancer. Correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 1987;235:177-82
13. Ross JS, Fletcher JA. The Her-2/neu oncogene in breast cancer: Prognostic factor, prediction factor and target for therapy. Oncologist 1998;3(4):237-52
14. Huang WY, Newman B, Millikan RC, et al. Risk of breast cancer according to the status of Her-2/neu oncogene amplification. Cancer epidemiology biomarkers & Prevention 2000;9:65-71
15. Nieto Y, Cagnoni PJ, Nawaz S, et al. Evaluation of the predictive value of Her-2/neu over expression and p53 mutations in high risk primary brest cancer patients treated with high dose chemotherapy and autologous stem cell transplantation. J Clin Oncol 2000;18(10):2070-80
16. Guerra I, Algorta J, Díaz de Otazu R. Immunohistochemical prognostic index for breast cancer in young women. Molecular Pathology 2003;56:323-7
17. Smith CA, Pollice AA, Gu LP et al. Correlations among p53, Her-2/neu and ras over expression and aneuploidy by multiparameter flow cytometry in human breast cancer: Evidence for a common phenotypic evolutionary pattern in infilterating ductal carcinoma. Clinical Cancer Res 2000;16:112-6
18. Marks JR, Humphrey PA, Wu K, et al. Over expression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 1994;219(4):332-41
19. Tsutsui S, Ohno S, Murakami S, et al. Prognostic significance of the coexpression of p53 protein and c-erbB2 in breast cancer. Am J Surg 2003;185(2):165-7
20. Konecny G, Pauletti G, Pegram M, et al. Quantitive associated between Her-2/neu and steroid hormone receptors-positive primary breast cancer. JNCI 2003;95(2):142-53
21. Thor A. Are patterns of Her-2/neu amplification and expression among primary and regional metastasis indicative of distance metastasis and predictive of herceptin response? JNCI 2001;93(15):1112-21
22. Menard S, Frotis S, Castiglioni F, et al. HER-2 as a prognostic factor in breast cancer. Oncology 2001;61(suppl 2):67-72
23. Swede H, Moysich KB, Winston JS et al. Variation of the prognostic significance of Her-2 expression in breast cancer according to tumor size. Breast J. 2003 Mar-Apr; 9(2):98-105
24. Ray A, Sharma BK, Kaur S, et al. Over expression of c-erbB2 oncoprotein and associated pathobiological factors in invasive primary breast cancer. Indian J Exp Biol 2004;42(3):253-8
25. Climent MA, Segui MA, Molina R, et al. Prognostic value of HER-2/neu and p53 expression in node positive breast cancer. HER-2/neu effect on adjuvant tamoxifen treatment. Breast 2001;10(1):67-77
26. Sutterlin MW, Haller A, Gassel AM, et al. The correlation of c-erbB2 oncoprotein and established prognostic factors in human breast cancer. Anticancer Res 2000;20(6D):5083-8
27. Korkolis DP, Tsoli E, Fouskakis D, et al. Tumor histology and stage but not p53, Her-2/neu or cathepsin-D expressions are independent prognostic factors in breast cancer patients. Anticancer Res 2004;24(3b):2061-8
28. Nishikawa K, Satoh H, Hirai, A et al. alpha-Tocopheryloxy butyric acid enhances necrotic cell death in breast cancer cell treated with chemotherapy agent. Cancer lett. 2003;201(1):51-6
29. Bobrow LG, Happerfield LG, Gregory WM, et al. Ductal carcinoma in situ: assessment of necrosis and nuclear morphology and their association with biological markers. J Path 1995; 176(4):333-41
30. Yagata H, Hariaga K, Suzuki M et al. Comedonecrosis is an unfavorable marker in node negative invasive breast carcinoma. Pathol Int 2003; 53(8):501-6
31. Egeblad M, Jattela M. Cell death induced by TNF or serum starvation is indepent of erbB receptor signaling in MCF-7 breast carcinoma cells. Int J Cancer 2000;86(5):617-25
32. Adebamowo CA, Ogundiran A, Kang EE, et al. Somatic p53 and HER-2/neu in Nigerian breast cancer. Proc Am Clin Oncol 2003;22:885